AI Medical Science Liaison platform

The AI MedicalScience Liaison

Voice-powered scientific exchange for your HCPs. Cited. Compliant. Always available.

Built for Medical Affairs teams at innovative pharma companies

How Dalil works

An AI agent that becomes your brand's Medical Science Liaison

01

Your AI agent learns your science

Upload your prescribing information, clinical study reports, publications, and congress data into a secure, closed-loop environment. Dalil's AI agent doesn't just store this content — it deeply understands it, building a comprehensive knowledge base of your brand's clinical evidence, endpoints, safety data, and approved claims.

The agent can only respond using your approved content. No hallucinations. No off-label speculation. Every response is traceable to a source document and page number.
02

You set the guardrails — the agent follows them

Upload your compliance documents at the company, therapeutic area, or team level — and your AI agent will digest and comply with them automatically. Guardrails stack: company-wide policies apply across every brand, therapeutic area rules layer on top, and team-level guidelines refine further. Define prohibited topics, required disclaimers, escalation triggers, and response boundaries. Your AI agent internalizes all layers and enforces them in every conversation — without exception.

Whether it's off-label inquiry handling, adverse event awareness, or competitor comparison boundaries — your agent operates within the exact compliance framework your medical, legal, and regulatory teams approve.
03

Your agent has voice conversations with HCPs

Invite healthcare professionals to a Virtual MSL Visit. They click a secure link, and your AI agent greets them by name and conducts a natural, voice-based scientific discussion — citing your clinical data, respecting your guardrails, and answering questions with the depth and precision of a senior MSL.

No chatbot. No typing. A real conversation. HCPs speak naturally, and the agent responds with cited, compliant clinical data in a professional voice. After each visit, the HCP receives a detailed transcript with every source referenced.
04

Every conversation generates intelligence

Your AI agent doesn't just answer questions — it listens. Every conversation is analyzed to extract what HCPs are asking about, what competitors they're evaluating, what clinical scenarios they face, and where your content library has gaps. This intelligence compounds over time, giving your medical affairs team visibility no field force could match.

Trending topics. Competitor signals. Content gap alerts. HCP interest profiles. AI-generated intelligence reports. All automatic, all from real scientific conversations.

See Dalil in action

A Virtual MSL Visit — from invitation to intelligence

dalil.bio
Inbox
Medical Affairs Weekly · Summary for March...
CME Credits · Your Q1 2026 summary is ready...
D
Dalil — Arovan Biosciences
Virtual MSL Visit: Zeltrivo (corivantrel)
Just now
Virtual MSL Visit
Dr. Smith, you've been invited to discuss the latest clinical data on Zeltrivo (corivantrel).
Begin Your Visit
This link expires in 48 hours
Zeltrivo · corivantrel
Virtual MSL Visit02:34
"What were the primary efficacy endpoints in the HORIZON-3 trial?"
Virtual MSL Visit Transcript
Dr. Smith · Zeltrivo (corivantrel) · Arovan Biosciences · March 15, 2026
Summary
Key topics: primary efficacy endpoints, HbA1c reduction data, safety profile overview. Dr. Smith expressed particular interest in the cardiovascular outcomes data.
Dr. Smith
What were the primary efficacy endpoints in the HORIZON-3 trial?
Dalil
The HORIZON-3 trial evaluated corivantrel versus placebo in adults with type 2 diabetes. The primary endpoint was change in HbA1c from baseline at 26 weeks...[1][2]
Dr. Smith
And what about the cardiovascular safety data?
Intelligence Dashboard · Zeltrivo
Visits this month
0
Unique HCPs
0
Questions answered
0%
Top topics
HbA1c efficacy60%
CV outcomes35%
Dosing20%
Content Gap
3 HCPs asked about pediatric data — not in current library
Competitor Mention
Competing therapy mentioned in 40% of visits — efficacy comparison

HCPs receive a secure invitation

Simulated demo — illustrates the Virtual MSL Visit experience

Built for regulated science

Every feature designed for pharma compliance from day one.

Voice-first scientific exchange

HCPs talk to Dalil like they'd talk to an MSL. Natural conversation, not a chatbot. A cited transcript is emailed after every visit.

Every claim cited

Responses are sourced exclusively from your approved content. Every statement is traceable to a specific document and page.

Compliance by design

Closed-loop guardrails, adverse event awareness, full audit trail. Company, TA, and brand policies stack automatically.

Intelligence that compounds

Each conversation builds a deeper understanding of what your HCPs need, think, and ask. Content gaps surface automatically.

Ready to transform your Medical Affairs strategy?

Currently onboarding select pharma and biotech companies.